James A Eastham1, Gregory B Auffenberg2, Daniel A Barocas3, Roger Chou4, Tony Crispino5, John W Davis6, Scott Eggener7, Eric M Horwitz8, Christopher J Kane9, Erin Kirkby10, Daniel W Lin11, Sean M McBride1, Alicia K Morgans12, Phillip M Pierorazio13, George Rodrigues14, William W Wong15, Stephen A Boorjian16. 1. Memorial Sloan Kettering Cancer Center, New York, New York. 2. Urology of St. Louis, St. Louis, Missouri. 3. Vanderbilt University Medical Center, Nashville, Tennessee. 4. Oregon Health & Science University, Portland, Oregon. 5. UsTOO, Las Vegas, Nevada. 6. MD Anderson Cancer Center, Houston, Texas. 7. The University of Chicago Medicine, Chicago, Illinois. 8. Fox Chase Cancer Center, Philadelphia, Pennsylvania. 9. UC San Diego Health Physician Group, San Diego, California. 10. American Urological Association, Linthicum, Maryland. 11. University of Washington Medical Center, Seattle, Washington. 12. Dana-Farber Cancer Institute, Boston, Massachusetts. 13. Penn Medicine, Philadelphia, Pennsylvania. 14. London Health Sciences Centre, London, Ontario, Canada. 15. Mayo Clinic, Phoenix, Arizona. 16. Mayo Clinic, Rochester, Minnesota.
Abstract
PURPOSE: The summary presented herein represents Part II of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles of active surveillance and surgery as well as follow-up for patients after primary treatment. Please refer to Parts I and III for discussion of risk assessment, staging, and risk-based management (Part I), and principles of radiation and future directions (Part III). MATERIALS AND METHODS: The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. A research librarian conducted searches in Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. The methodology team supplemented searches of electronic databases with the studies included in the prior AUA review and by reviewing reference lists of relevant articles. RESULTS: The Clinically Localized Prostate Cancer Panel created evidence- and consensus-based guideline statements to aid clinicians in the management of patients with clinically localized prostate cancer. Statements regarding active surveillance, surgical management, and patient follow-up are detailed. CONCLUSION: This guideline aims to inform clinicians treating patients with clinically localized prostate cancer. Continued research and publication of high-quality evidence from future trials will be essential to further improve care for these men.
PURPOSE: The summary presented herein represents Part II of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles of active surveillance and surgery as well as follow-up for patients after primary treatment. Please refer to Parts I and III for discussion of risk assessment, staging, and risk-based management (Part I), and principles of radiation and future directions (Part III). MATERIALS AND METHODS: The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. A research librarian conducted searches in Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. The methodology team supplemented searches of electronic databases with the studies included in the prior AUA review and by reviewing reference lists of relevant articles. RESULTS: The Clinically Localized Prostate Cancer Panel created evidence- and consensus-based guideline statements to aid clinicians in the management of patients with clinically localized prostate cancer. Statements regarding active surveillance, surgical management, and patient follow-up are detailed. CONCLUSION: This guideline aims to inform clinicians treating patients with clinically localized prostate cancer. Continued research and publication of high-quality evidence from future trials will be essential to further improve care for these men.
Entities:
Keywords:
Active surveillance; Prostate cancer; Radiation therapy for prostate cancer; Radical prostatectomy; Shared decision making